Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne

Launched by XIYUAN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES · Mar 13, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment for moderate to severe acne called Photodynamic Therapy (PDT) using a substance called Chlorin-e6. The researchers want to find out how effective this therapy is, as well as how safe and tolerable it is for patients. If you are between the ages of 18 and 50 and have been struggling with moderate to severe acne on your face, you may be eligible to participate in this study.

Participants will need to sign a consent form, and they will be closely monitored throughout the treatment process. However, some individuals may not qualify, such as those who are pregnant, have certain skin conditions, or have recently used specific medications. This trial is currently recruiting participants, and it offers a chance to explore a potential new way to manage acne that could lead to better skin health. If you think you might be interested, it’s a good idea to talk with your healthcare provider for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject is male or non-pregnant female 18 years of age and younger than 50 years of age.
• • 2. Subject has moderate to severe facial acne vulgaris.
• • 3. Subject has provided written informed consent.
• Exclusion Criteria:
• • 1. People who are taking photosensitive drugs;
• • 2. Allergic to any component of the photosensitizer;
• • 3. porphyrins or allergies to porphyrins, with a history of photosensitivity;
• • 4. Pregnant or lactating women and those planning to become pregnant within 3 months;
• • 5. Oral or topical antibiotics, retinoids, glucocorticoids, peroxybenzoyl and other drugs within the past 1 month;
• • 6. Have a history of exposure to sunlight in the past 1 month, have received photoelectric treatment in the past 3 months, or have received facial grinding treatment in the past six months;
• • 7. are using vasodilators (such as nitroglycerin, etc.), beta blockers (such as metoprolol, etc.), anticoagulants (such as warfarin, etc.) and other drugs that easily cause facial capillary dilatation;
• • 8. Patients with facial rosacea, atopic dermatitis, hormone-dependent dermatitis and other facial skin-related diseases;
• • 9. Abnormal blood and urine routine, liver and kidney function, diseases of important organs and hematopoietic system that researchers believe are not suitable for clinical trials;
• • 10. Patients participating in other clinical trials at the same time.